Skip to main content
SINOTHERAPEUTICS INC. logo

SINOTHERAPEUTICS INC. — Investor Relations & Filings

Ticker · 688247 ISIN · CNE100005PL9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2024-04-29 Annual Report
Country CN China
Listing Shanghai Stock Exchange 688247

About SINOTHERAPEUTICS INC.

https://www.sinotph.com/en/

Sinotherapeutics Inc. is a pharmaceutical company specializing in the research, development, and commercialization of complex generic drugs and innovative drug delivery systems. The company focuses on high-barrier formulations, particularly oral solid dosage forms with modified-release or controlled-release profiles. Utilizing advanced technology platforms, Sinotherapeutics develops products designed to improve patient compliance and therapeutic outcomes. Its operations encompass the full lifecycle of drug development, from formulation design and clinical evaluation to large-scale manufacturing under global quality standards. The company maintains a robust pipeline targeting various therapeutic areas, including cardiovascular diseases, central nervous system disorders, and metabolic conditions. Sinotherapeutics aims to provide high-quality, affordable medications by leveraging its expertise in complex chemistry and pharmaceutical engineering.

Recent filings

Filing Released Lang Actions
2023年年度报告
Annual Report Classification · 100% confidence The document is titled "2023 年年度报告" which translates to "2023 Annual Report". It contains detailed financial data, management discussion and analysis, company overview, risk factors, governance, and audited financial statements. The length is substantial (15,000 characters), and it includes comprehensive financial and operational information for the fiscal year 2023. The presence of audited financial statements and management analysis confirms it is the full annual report itself, not just an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K).
2024-04-29 Chinese
关于自愿披露2024年第一季度业绩预告的公告
Earnings Release Classification · 95% confidence The document is a voluntary disclosure announcement of the company's 2024 first quarter earnings forecast. It provides preliminary estimated financial figures for the quarter but explicitly states that the data is unaudited and preliminary, and that the official detailed financial report will be published later. The document length is short (933 characters) and it does not contain actual financial statements or detailed analysis, only forecasted figures and explanations. Therefore, it is not an Interim/Quarterly Report (IR) but rather an Earnings Release (ER) since it announces key financial highlights for the quarter. It is not a full report or a regulatory filing or a report publication announcement. Hence, the correct classification is Earnings Release (ER).
2024-04-16 Chinese
关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding the progress of its share repurchase program through centralized bidding transactions. It details the number of shares repurchased, prices, total funds used, and references the board meeting approving the repurchase plan. The document does not contain financial statements or detailed financial analysis but reports on the company's share buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company announcements about buying back its own shares.
2024-04-01 Chinese
关于持股5%以上股东部分股份解除质押及质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding the pledge and release of pledged shares by a shareholder holding more than 5% of the company's shares. It details the number of shares pledged and released, the proportion of total shares, and related information about the shareholder's stock pledge status. There is no financial report, earnings data, or management discussion. The document is a regulatory disclosure about share pledging activities, which fits the category of Major Shareholding Notification (MRQ) as it involves significant shareholding changes and related pledging information.
2024-03-14 Chinese
关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding the progress of its share repurchase program through centralized bidding transactions. It details the number of shares repurchased, the price range, total funds used, and references the board meeting approving the repurchase plan. The document does not contain financial statements or detailed financial analysis but reports on the company's share buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company announcements about buying back its own shares.
2024-03-01 Chinese
关于以集中竞价交易方式首次回购公司股份的公告
Transaction in Own Shares Classification · 100% confidence The document is a formal announcement by Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding the company's first share repurchase through centralized bidding on the Shanghai Stock Exchange. It details the number of shares repurchased, prices, total funds used, and references the board meeting approving the repurchase plan. The content focuses on the share buyback transaction itself, including regulatory compliance and future plans for the repurchased shares. There is no financial statement or comprehensive report data, nor is it a report publication announcement. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company buyback activities.
2024-02-26 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.